{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:33:07Z","timestamp":1793640787246,"version":"4.5.1"},"reference-count":68,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/14712598.2026.2743869","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:58:58Z","timestamp":1791194338000},"page":"1209-1218","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Redefining breast cancer treatment by precision oncology: the clinical impact of sacituzumab govitecan"],"prefix":"10.1080","volume":"26","author":[{"given":"Vincenzo","family":"Di Lauro","sequence":"first","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Claudia","family":"Sacco","sequence":"additional","affiliation":[{"name":"S.G. Moscati Hospital","place":["Avellino, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Palma","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi della Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"von Arx","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Buono","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piezzo","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cocco","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Vitale","sequence":"additional","affiliation":[{"name":"Macerata Hospital","place":["Macerata, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[{"name":"Macerata Hospital","place":["Macerata, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Gridelli","sequence":"additional","affiliation":[{"name":"ASL Bari","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[{"name":"Napoli","place":["Italy"]},{"name":"Clinical and Translational Oncology","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Tumori \u2018Giovanni Paolo II\u2019","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccimarra","sequence":"additional","affiliation":[{"name":"TDM, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[{"name":"TDM, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-253"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3475-2"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1701"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0215(19980119)75:2<324:aid-ijc24>3.0.co;2-b"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25615"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00341-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-022-01389-3"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2107"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213"},{"key":"e_1_3_4_14_1","volume-title":"[Highlights of prescribing information]","author":"Trodelvy (sacituzumab govitecan-hzly)","year":"2023","unstructured":"Trodelvy (sacituzumab govitecan-hzly). [Highlights of prescribing information]. Foster City (CA): Gilead Sciences, Inc.; 2023 [cited 2023 Dec 7]."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102672"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910620419"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00223"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0163"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144919"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0375"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1525"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104979"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01884-9"},{"issue":"8","key":"e_1_3_4_25_1","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen RH","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182\u20132194.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0644-7"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1319123110"},{"key":"e_1_3_4_28_1","volume-title":"National library of medicine","author":"PubChem Sacituzumab govitecan","unstructured":"PubChem Sacituzumab govitecan. National library of medicine. NIH."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70060"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1632115"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58009-3"},{"key":"e_1_3_4_32_1","unstructured":"TRODELVY. Prescribing information. 2020 [cited 2021 Jan 15]. Available from: https:\/\/trodelvy.com\/pdf\/PrescribingInformation.pdf"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020574"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30789"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390094"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102113"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2771"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3321"},{"key":"e_1_3_4_41_1","unstructured":"Camptosar - irinotecan hydrochloride injection solution (prescribing information package insert). 2012. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=533:Pfizer"},{"key":"e_1_3_4_42_1","volume-title":"Common terminology criteria for adverse events (CTCAE - Version 5.0)","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE - Version 5.0). Bethesda (MD): US Department of Health and Human Service, National Institutes of Health; 2017."},{"key":"e_1_3_4_43_1","unstructured":"Bardia A Starodub A Moroose RL et al. IMMU-132 a new antibody-drug conjugate (ADC) against Trop-2 as a novel therapeutic for patients with relapsed\/refractory metastatic triple-negative breast cancer (TNBC): results from phase I\/II clinical trial (NCT01631552)."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8297"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.004"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0428"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1102"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508959"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.511"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.018"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-GS1-09"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01002"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02589-x"},{"key":"e_1_3_4_59_1","unstructured":"US Food and Drug Administration. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. 2026. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.002"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.017"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.03.008"},{"key":"e_1_3_4_67_1","unstructured":"US Food and Drug Administration. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer. 2026. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00748-5"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02766-9"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00898"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2743869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2743869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2743869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:23:15Z","timestamp":1793640195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2743869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/14712598.2026.2743869"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2743869","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}